Published in Cell Cycle on August 28, 2010
Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle (2010) 3.00
Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. Cell Cycle (2011) 2.92
Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle (2011) 2.91
Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle (2010) 2.80
Cytokine production and inflammation drive autophagy in the tumor microenvironment: role of stromal caveolin-1 as a key regulator. Cell Cycle (2011) 2.68
Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle (2011) 2.67
Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle (2012) 2.55
Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle (2011) 2.39
Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol (2015) 2.35
The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle (2010) 2.26
Targeting lactate metabolism for cancer therapeutics. J Clin Invest (2013) 2.14
The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox. Cell Cycle (2010) 2.10
Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev (2013) 2.05
Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid Redox Signal (2011) 2.04
Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. Int J Biochem Cell Biol (2011) 1.97
Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. Cancer Biol Ther (2010) 1.96
Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle (2011) 1.92
HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. Cell Cycle (2010) 1.89
Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Nat Rev Cancer (2014) 1.89
Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance. Cancer Biol Ther (2011) 1.85
Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol (2016) 1.83
Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors. Cell Cycle (2011) 1.82
Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res (2011) 1.80
Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res (2012) 1.73
Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. Cell Cycle (2012) 1.63
Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res (2012) 1.55
Mitochondrial targeted catalase suppresses invasive breast cancer in mice. BMC Cancer (2011) 1.54
Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. Cancer Biol Ther (2011) 1.48
Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells. Cell Cycle (2011) 1.46
Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol (2012) 1.45
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther (2011) 1.43
CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle (2012) 1.37
Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs "fertilizer". Cell Cycle (2011) 1.36
Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells. Cell Cycle (2011) 1.32
Autophagy and cancer cell metabolism. Semin Cell Dev Biol (2012) 1.32
Autophagy and cancer. Cold Spring Harb Perspect Biol (2012) 1.30
Killing a cancer: what are the alternatives? Nat Rev Cancer (2012) 1.30
CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle (2012) 1.29
Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: connecting TGF-β signaling with "Warburg-like" cancer metabolism and L-lactate production. Cell Cycle (2012) 1.29
Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection. Cell Cycle (2011) 1.29
Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention? BMC Med (2011) 1.26
Accelerated aging in the tumor microenvironment: connecting aging, inflammation and cancer metabolism with personalized medicine. Cell Cycle (2011) 1.24
Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the "reverse Warburg effect" in positive lymph node tissue. Cell Cycle (2012) 1.23
Lymph node stroma broaden the peripheral tolerance paradigm. Trends Immunol (2010) 1.22
Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. Cell Cycle (2012) 1.22
Cell-mediated autophagy promotes cancer cell survival. Cancer Res (2012) 1.21
Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth. Oncotarget (2012) 1.20
Oxidative stress in angiogenesis and vascular disease. Blood (2013) 1.19
Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol (2014) 1.16
Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer. Clin Cancer Res (2012) 1.15
Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer. Cell Cycle (2013) 1.14
Targeting AMPK for cancer prevention and treatment. Oncotarget (2015) 1.13
Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells. Cell Cycle (2012) 1.13
Role of oxidative stress and the microenvironment in breast cancer development and progression. Adv Cancer Res (2013) 1.12
STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget (2012) 1.12
Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer. Cell Death Dis (2014) 1.08
Obesity, metabolism and the microenvironment: Links to cancer. J Carcinog (2013) 1.07
Identification of NCF2/p67phox as a novel p53 target gene. Cell Cycle (2012) 1.07
Oncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery. Cell Cycle (2013) 1.07
Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett (2013) 1.06
Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. Cancer Biol Ther (2011) 1.05
You are what you eat: within-subject increases in fruit and vegetable consumption confer beneficial skin-color changes. PLoS One (2012) 1.05
Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype. Breast Cancer Res (2013) 1.05
Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. ScientificWorldJournal (2011) 1.04
Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy. Redox Biol (2014) 1.04
Role of mesenchymal stem cells in osteosarcoma and metabolic reprogramming of tumor cells. Oncotarget (2014) 1.03
BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies. Cell Cycle (2012) 1.00
Is cancer a metabolic disease? Am J Pathol (2013) 0.99
Cancer metabolism: new validated targets for drug discovery. Oncotarget (2013) 0.97
MicroRNAs in pancreatic cancer metabolism. Nat Rev Gastroenterol Hepatol (2012) 0.97
Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFκB target stromal MCT4. Cell Cycle (2013) 0.97
Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol (2015) 0.97
The nutritional phenome of EMT-induced cancer stem-like cells. Oncotarget (2014) 0.96
Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma. Cell Cycle (2012) 0.95
Differential expression of enzymes associated with serine/glycine metabolism in different breast cancer subtypes. PLoS One (2014) 0.95
Autophagy in breast cancer and its implications for therapy. Am J Cancer Res (2013) 0.94
Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages. PLoS One (2015) 0.91
Appealing to vanity: could potential appearance improvement motivate fruit and vegetable consumption? Am J Public Health (2011) 0.90
Caveolin-1, cellular senescence and age-related diseases. Mech Ageing Dev (2011) 0.90
Mitochondrial biogenesis drives tumor cell proliferation. Am J Pathol (2011) 0.90
The role of autophagy induced by tumor microenvironment in different cells and stages of cancer. Cell Biosci (2015) 0.88
Lithocholic bile acid selectively kills neuroblastoma cells, while sparing normal neuronal cells. Oncotarget (2011) 0.88
Oxidation as "the stress of life". Aging (Albany NY) (2011) 0.87
Cigarette smoke metabolically promotes cancer, via autophagy and premature aging in the host stromal microenvironment. Cell Cycle (2013) 0.87
Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer. Front Oncol (2015) 0.87
Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go. Cancers (Basel) (2016) 0.86
Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front Pharmacol (2013) 0.86
Janus-faced tumor microenvironment and redox. Antioxid Redox Signal (2014) 0.85
Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res (2015) 0.85
Value of caveolin-1 in cancer progression and prognosis: Emphasis on cancer-associated fibroblasts, human cancer cells and mechanism of caveolin-1 expression (Review). Oncol Lett (2014) 0.84
A microfluidic co-culture system to monitor tumor-stromal interactions on a chip. Biomicrofluidics (2014) 0.83
Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer (2014) 0.82
Compartment-specific activation of PPARγ governs breast cancer tumor growth, via metabolic reprogramming and symbiosis. Cell Cycle (2013) 0.82
Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment. Antioxid Redox Signal (2014) 0.82
Impaired mitochondrial metabolism and mammary carcinogenesis. J Mammary Gland Biol Neoplasia (2012) 0.82
The reverse Warburg effect in osteosarcoma. Oncotarget (2014) 0.81
Curcumin attenuates high glucose-induced podocyte apoptosis by regulating functional connections between caveolin-1 phosphorylation and ROS. Acta Pharmacol Sin (2016) 0.81
Transcriptional evidence for inferred pattern of pollen tube-stigma metabolic coupling during pollination. PLoS One (2014) 0.81
Role of nitric oxide in the radiation-induced bystander effect. Redox Biol (2015) 0.81
Critical transitions in a game theoretic model of tumour metabolism. Interface Focus (2014) 0.81
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature (2008) 18.20
Mitochondria, oxidants, and aging. Cell (2005) 16.11
The antioxidant function of the p53 tumor suppressor. Nat Med (2005) 7.57
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest (2008) 7.52
Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem (2001) 7.03
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A (1998) 6.90
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res (2009) 6.74
Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol (2000) 6.49
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle (2009) 4.69
Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J Biol Chem (1997) 3.80
Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care (2010) 3.68
Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. Mol Cell (2004) 3.43
A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase. Nat Genet (1998) 3.41
An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol (2009) 3.15
Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int (2010) 3.08
Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci U S A (1995) 3.03
Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem (1996) 3.01
Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene (1998) 2.59
p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem (1996) 2.56
Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst (1998) 2.50
Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol (2009) 2.44
Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res (2009) 2.34
Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem (1997) 2.34
Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle (2010) 2.32
Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther (2009) 2.25
Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J (1998) 2.23
Mitochondria in cancer: not just innocent bystanders. Semin Cancer Biol (2008) 2.23
Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J Clin Invest (1996) 2.20
Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression. Genes Dev (1998) 1.99
Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther (2010) 1.99
Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling". Aging (Albany NY) (2010) 1.88
An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle (2009) 1.88
Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol (2009) 1.87
Evidence for field cancerization of the prostate. Prostate (2009) 1.86
Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol Ther (2008) 1.79
Differences in assembly or stability of complex I and other mitochondrial OXPHOS complexes in inherited complex I deficiency. Hum Mol Genet (2004) 1.71
Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol (1992) 1.61
Accumulation of HIF-1alpha under the influence of nitric oxide. Blood (2001) 1.55
The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr (2006) 1.51
Ultrastructure of the mitochondrion and its bearing on function and bioenergetics. Antioxid Redox Signal (2008) 1.50
Normoxic stabilization of hypoxia-inducible factor-1 expression and activity: redox-dependent effect of nitrogen oxides. Mol Pharmacol (2000) 1.47
Ultrastructure of the human mammary gland. Pathol Annu (1971) 1.46
Effect of N-acetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice. Cancer Res (2004) 1.43
Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J (2008) 1.41
The hydra phenomenon of cancer: why tumors recur locally after microscopically complete resection. Cancer Res (2005) 1.38
Antioxidant N-acetyl cysteine reduces incidence and multiplicity of lymphoma in Atm deficient mice. DNA Repair (Amst) (2006) 1.32
Nitric oxide in breast cancer: induction of vascular endothelial growth factor-C and correlation with metastasis and poor prognosis. Clin Cancer Res (2006) 1.31
Enterococcus faecalis induces aneuploidy and tetraploidy in colonic epithelial cells through a bystander effect. Cancer Res (2008) 1.29
Clonality and field cancerization in intraductal papillary-mucinous tumors of the pancreas. Cancer (2001) 1.29
Myofibroblasts in the stroma of invasive and metastatic carcinoma: a possible host response to neoplasia. Am J Surg Pathol (1979) 1.27
Postischemic inhibition of cerebral cortex pyruvate dehydrogenase. Free Radic Biol Med (1994) 1.26
Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int J Cancer (2006) 1.25
Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res (2000) 1.22
Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. Am J Physiol Cell Physiol (2001) 1.17
Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res (2010) 1.15
Nitric oxide, an autocrine regulator of wound fibroblast synthetic function. J Immunol (1997) 1.15
Relationships between caveolae and eNOS: everything in proximity and the proximity of everything. Am J Physiol Renal Physiol (2002) 1.11
Antioxidants suppress lymphoma and increase longevity in Atm-deficient mice. J Nutr (2007) 1.07
Genetic variability in iron-related oxidative stress pathways (Nrf2, NQ01, NOS3, and HO-1), iron intake, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.05
Human dermal fibroblasts produce nitric oxide and express both constitutive and inducible nitric oxide synthase isoforms. J Invest Dermatol (1996) 1.05
Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice. Carcinogenesis (2005) 1.01
Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism. Biochemistry (2001) 0.99
Peroxiredoxin I and II inhibit H2O2-induced cell death in MCF-7 cell lines. J Cell Biochem (2007) 0.98
Nitric oxide drives skin repair: novel functions of an established mediator. Kidney Int (2002) 0.97
Impact of culture conditions, culture media volumes, and glucose content on metabolic properties of renal epithelial cell cultures. Are renal cells in tissue culture hypoxic? Cell Physiol Biochem (1999) 0.97
Chronic myocardial hypoxia increases nitric oxide synthase and decreases caveolin-3. Free Radic Biol Med (2000) 0.95
NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice. Br J Cancer (1996) 0.95
Relationships between polymorphisms in NOS3 and MPO genes, cigarette smoking and risk of post-menopausal breast cancer. Carcinogenesis (2007) 0.93
Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect. Rejuvenation Res (2010) 0.89
Could stroma contribute to field cancerization? Med Hypotheses (2010) 0.88
Increasing oxidative damage and loss of mismatch repair enzymes during breast carcinogenesis. Eur J Cancer (2006) 0.87
Effects of NG-nitro-L-arginine and/or L-arginine on experimental pulmonary metastasis in mice. Cancer Lett (1994) 0.85
Aneuploidy fraction but not DNA index is important for the prognosis of patients with stage I and II breast cancer--10-year results. Ann Oncol (1993) 0.84
mitoEnergetics and cancer cell fate. Biochim Biophys Acta (2008) 0.83
Mathematical modelling of nitric oxide activity in wound healing can explain keloid and hypertrophic scarring. J Theor Biol (2000) 0.83
Antioxidative response for nitric oxide production in breast carcinoma. Oncol Rep (2004) 0.81
Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. APMIS Suppl (2003) 0.81
Association between nitrotyrosine levels and microvascular density in human breast cancer. Breast Cancer Res Treat (2002) 0.81
NG-nitro-L-arginine methyl ester inhibits bone metastasis after modified intracardiac injection of human breast cancer cells in a nude mouse model. Jpn J Cancer Res (1997) 0.80
[Immunohistochemical study on expression of iNOS and eNOS during skin incised wound healing in mice]. Fa Yi Xue Za Zhi (2005) 0.80
Timing of supplementation with the antioxidant N-acetyl-L-cysteine reduces tumor multiplicity in novel, cancer-prone p53 haploinsufficient Tg.AC (v-Ha-ras) transgenic mice but has no impact on malignant progression. Nutr Cancer (2002) 0.80
The role of nitric oxide in the formation of keloid and hypertrophic lesions. Med Hypotheses (2001) 0.78
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood (2007) 9.82
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol (2008) 8.70
Adjuvant docetaxel for node-positive breast cancer. N Engl J Med (2005) 8.00
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol (2010) 5.93
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
Minireview: Cyclin D1: normal and abnormal functions. Endocrinology (2004) 5.22
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol (2010) 4.75
The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle (2009) 4.69
Role of caveolae and caveolins in health and disease. Physiol Rev (2004) 4.55
Caveolae: from cell biology to animal physiology. Pharmacol Rev (2002) 4.45
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol (2009) 4.20
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst (2007) 4.11
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet (2013) 3.87
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst (2011) 3.73
Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J Biol Chem (2001) 3.54
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol (2004) 3.50
Reversion of gene expression alterations in hearts of mice with chronic chagasic cardiomyopathy after transplantation of bone marrow cells. Cell Cycle (2011) 3.49
MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat (2014) 3.46
Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol (2005) 3.20
A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol (2005) 3.19
An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol (2009) 3.15
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle (2010) 3.00
Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. Cell Cycle (2011) 2.92
Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle (2011) 2.91
Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle (2010) 2.80
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
Perilipin A mediates the reversible binding of CGI-58 to lipid droplets in 3T3-L1 adipocytes. J Biol Chem (2004) 2.76
The Caveolin genes: from cell biology to medicine. Ann Med (2004) 2.68
Cytokine production and inflammation drive autophagy in the tumor microenvironment: role of stromal caveolin-1 as a key regulator. Cell Cycle (2011) 2.68
Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci U S A (2007) 2.67
Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle (2011) 2.67
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol (2010) 2.63
SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem (2005) 2.59
Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle (2012) 2.55
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev (2008) 2.48